Back to journals
Academic JournalOpen Access

Frontiers in Neuroscience

18 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 18 psychedelic papers Blossom tracks from Frontiers in Neuroscience line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Frontiers in Neuroscience carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

4papers published in 2023

+33% vs 2022

15 published by 2023

Browse papers→

Don't read as the journal's total output: only the 18 of 18 tracked psychedelic papers from Frontiers in Neuroscience with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Frontiers in Neuroscience publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
8
Anxiety Disorders
4
Addiction & Substance Use
3
Immunology & Inflammation
3
Neuroimaging & Brain Measures
3
PTSD
3
Older Adults
2
Suicidality
2
Other
13

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Frontiers in Neuroscience cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ketamine
3
MDMA
2
Ayahuasca
2
DMT
2
Psilocybin
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Frontiers in Neuroscience has 18 tracked papers indexed in Blossom (2016–2026) from 75 authors, most often covering Ketamine, MDMA and Ayahuasca, across Depressive Disorders, Anxiety Disorders and Immunology & Inflammation.

Published Papers

Open Accessindividual

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report

This case report describes an octogenarian woman with advanced Alzheimer’s disease who received 5 g of psilocybin-containing mushrooms and then showed temporary improvements in speech, continence, movement, mood and social engagement. The acute effects included sweating, possible fever and a prolonged sleep-like state.

Published
Journal
Frontiers in Neuroscience
Authors
Lago, M., Cerveira, M., Simonet, J. X.
Open Accessindividual

Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study

This open-label exploratory study (n=23) examined inflammatory biomarkers in Veterans with PTSD during MDMA-assisted group therapy and found small changes in interleukin-6, tumour necrosis factor alpha and C-reactive protein. Higher baseline inflammation was linked with worse PTSD symptoms, and changes in interleukin-6 were related to symptom improvement.

Published
Journal
Frontiers in Neuroscience
Authors
Kachmarik, J. E., Loftis, J. M., Stauffer, C. S.
Open Accessindividual

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA

Using in vitro receptor profiling and rat RNA‑seq, the authors show methylone is a monoamine uptake inhibitor/releaser that rapidly upregulates neuroplasticity‑related genes in frontal cortex and regulates myelin‑related genes in the amygdala. Unlike MDMA, methylone showed no off‑target activity across 168 GPCRs, indicating greater specificity and supporting its potential as a PTSD treatment.

Published
Journal
Frontiers in Neuroscience
Authors
Schmidt, E. F., Warner-Schmidt, J., Stogniew, M., Mandell, B., Rowland, R. S., Kelmendi, B.
Open Accessmeta

The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression

This review (2023) focuses on the role of the ego in psychedelic-assisted psychotherapy (PAT), particularly through a psychodynamic lens. It argues that psychedelics induce regressed states of the ego, allowing for emotional integration of early life events that have shaped a person's character and defence mechanisms. The paper posits that for lasting change, PAT must target the characterological core of the ego's habitual patterns, and it suggests that this psycholytic approach is compatible with other forms of PAT like third-wave cognitive behavioural approaches (CBT/ACT).

Published
Journal
Frontiers in Neuroscience
Authors
Buchborn, T., Kettner, H., Kartner, L., Meinhardt, M. W.
Open Accessindividual

Cortical structural differences following repeated ayahuasca use hold molecular signatures

Using 7 T MRI and morphometric similarity networks in 24 Santo Daime members and matched controls, repeated ayahuasca use was associated with sensorimotor structural differentiation and transmodal de-differentiation across the cortex. These macroscale cortical remodellings spatially correlated with dysregulation of 5‑HT2A and other psychedelic-target genes, and with altered expression of transcription factors and immediate early genes implicated in psychedelic-induced neuroplasticity, suggesting molecular mechanisms scale up to whole-brain organisation.

Published
Journal
Frontiers in Neuroscience
Authors
Mallaroni, P., Mason, N. L., Kloft, L., Reckweg, J., van Oorsouw, K., Ramaekers, J. G.
Open Accessindividual

Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder

In 39 patients with major depressive disorder treated with six subanesthetic ketamine infusions, increased resting-state functional connectivity between the left amygdala and left medial superior frontal gyrus after treatment correlated with reduction in depressive symptoms, and baseline connectivity between the bilateral amygdalae and the right putamen predicted antidepressant and antisuicidal response (AUCs 0.739 and 0.827).

Published
Journal
Frontiers in Neuroscience
Authors
Wang, C., Lan, X-F., Zhou, Y.

Quick Facts

Papers Indexed
18
h-Index
170
Open Access
Yes
Publisher
Frontiers Media
Country
Switzerland
Website
Visit